Avadel Pharmaceuticals Plc Stock Short Ratio
| AVDL Stock | USD 17.38 0.61 3.39% |
Avadel Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Avadel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Avadel Stock. The fundamental analysis module provides a way to measure Avadel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avadel Pharmaceuticals stock.
Avadel | Short Ratio |
Avadel Pharmaceuticals PLC Company Short Ratio Analysis
Avadel Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Avadel Pharmaceuticals Short Ratio | 6.47 X |
Most of Avadel Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avadel Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avadel Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Avadel Pharmaceuticals is extremely important. It helps to project a fair market value of Avadel Stock properly, considering its historical fundamentals such as Short Ratio. Since Avadel Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avadel Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avadel Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Avadel Discontinued Operations
Discontinued Operations |
|
Based on the latest financial disclosure, Avadel Pharmaceuticals PLC has a Short Ratio of 6.47 times. This is 65.9% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The short ratio for all United States stocks is 61.75% lower than that of the firm.
Avadel Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avadel Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avadel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Avadel Pharmaceuticals by comparing valuation metrics of similar companies.Avadel Pharmaceuticals is currently under evaluation in short ratio category among related companies.
Avadel Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Avadel Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Avadel Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Avadel Pharmaceuticals' value.| Shares | Goldman Sachs Group Inc | 2023-12-31 | 974.5 K | Samsara Biocapital, Llc | 2023-12-31 | 967.5 K | Tri Locum Partners Lp | 2023-12-31 | 839.9 K | Balyasny Asset Management Llc | 2023-12-31 | 781.5 K | Mpm Oncology Impact Management Lp | 2023-12-31 | 665 K | Kennedy Capital Management Inc | 2023-12-31 | 645.9 K | Renaissance Technologies Corp | 2023-12-31 | 625.1 K | Knoll Capital Management Lp | 2023-12-31 | 600 K | Modera Wealth Management, Llc | 2023-12-31 | 598.4 K | Hhg Plc | 2023-12-31 | 11.1 M | Rtw Investments, Llc | 2023-12-31 | 6.9 M |
Avadel Fundamentals
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (1.28) % | ||||
| Current Valuation | 1.56 B | ||||
| Shares Outstanding | 90.58 M | ||||
| Shares Owned By Insiders | 4.89 % | ||||
| Shares Owned By Institutions | 64.13 % | ||||
| Number Of Shares Shorted | 10.39 M | ||||
| Price To Earning | 61.46 X | ||||
| Price To Book | 16.52 X | ||||
| Price To Sales | 51.79 X | ||||
| Revenue | 27.96 M | ||||
| Gross Profit | 16.59 M | ||||
| EBITDA | (136.08 M) | ||||
| Net Income | (160.28 M) | ||||
| Cash And Equivalents | 104.12 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 35.38 M | ||||
| Debt To Equity | 2.63 % | ||||
| Current Ratio | 2.72 X | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (132.87 M) | ||||
| Short Ratio | 6.47 X | ||||
| Earnings Per Share | (2.00) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 22.9 | ||||
| Number Of Employees | 154 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 1.57 B | ||||
| Total Asset | 261.13 M | ||||
| Retained Earnings | (745.5 M) | ||||
| Working Capital | 97.35 M | ||||
| Current Asset | 177.85 M | ||||
| Current Liabilities | 59.19 M | ||||
| Net Asset | 261.13 M |
About Avadel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avadel Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avadel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avadel Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Avadel Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Avadel Pharmaceuticals' short interest history, or implied volatility extrapolated from Avadel Pharmaceuticals options trading.
Pair Trading with Avadel Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Avadel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avadel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Avadel Stock
| 0.66 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.81 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
Moving against Avadel Stock
| 0.88 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.79 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.78 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.78 | ME | 23Andme Holding | PairCorr |
| 0.72 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Avadel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Avadel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Avadel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Avadel Pharmaceuticals PLC to buy it.
The correlation of Avadel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Avadel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Avadel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Avadel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Avadel Pharmaceuticals Piotroski F Score and Avadel Pharmaceuticals Altman Z Score analysis. Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Avadel Stock analysis
When running Avadel Pharmaceuticals' price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.349 | Quarterly Revenue Growth (1.00) | Return On Assets (0.58) | Return On Equity (4.81) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.